Profile data is unavailable for this security.
About the company
Fortrea Holdings Inc. is a global contract research organization (CRO). The Company is providing clinical development, patient access solutions and consulting to the life sciences industry. The Company provides phase I through IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. The Company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment offers solutions to the market that include clinical pharmacology and comprehensive clinical development capabilities. Its Enabling Services segment provides patient access and technology solutions that can be deployed as a standalone offering or across its global solutions depending on the scope of its customers’ needs. The Company offers its customers with clinical trial solutions through three delivery models: Full Service, Functional Service Provider, and Hybrid.
- Revenue in USD (TTM)3.01bn
- Net income in USD-102.40m
- Incorporated2023
- Employees18.00k
- LocationFortrea Holdings Inc8 Moore DriveDURHAM 27709United StatesUSA
- Fax+1 (302) 636-5454
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 2.12bn | 1.76k | 14.91 | 3.14 | 10.53 | 3.13 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.18bn | 1.54k | -- | -- | -- | 2.18 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.18bn | 500.00 | -- | 5.42 | -- | 47.09 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.18bn | 61.00 | -- | 3.83 | -- | 4,044.16 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.63 | -- | 12.61 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.22bn | 624.00 | -- | 14.42 | 464.70 | 7.83 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.24bn | 226.00 | -- | 36.39 | -- | 24.38 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -102.40m | 2.28bn | 18.00k | -- | 1.43 | -- | 0.7596 | -1.15 | -1.38 | 33.80 | 17.92 | 0.7027 | -- | 3.10 | -- | -2.39 | -- | -2.89 | -- | 16.64 | -- | -3.41 | -- | -- | 0.0877 | 0.5019 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.30bn | 497.00 | -- | 6.37 | -- | 8.66 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.34bn | 314.00 | 5,044.98 | 10.00 | 434.09 | 11.28 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.35bn | 64.00 | -- | 3.59 | -- | 322.83 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -116.03m | 2.37bn | 105.00 | -- | 53.67 | -- | -- | -0.1657 | -0.1657 | 0.00 | 0.063 | 0.00 | -- | -- | 0.00 | -53.76 | -77.32 | -59.38 | -86.35 | -- | -- | -- | -20,989.46 | -- | -118.81 | 0.6934 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.40bn | 526.00 | -- | 2.31 | -- | 45.56 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.41bn | 445.00 | -- | 3.95 | -- | 33.81 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.43bn | 160.00 | -- | 2.90 | -- | 400.76 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
Data as of May 24 2024. Currency figures normalised to Fortrea Holdings Inc's reporting currency: US Dollar USD
57.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 11.02m | 12.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.79m | 10.95% |
| Sessa Capital IM LPas of 31 Mar 2024 | 6.38m | 7.13% |
| Starboard Value LPas of 31 Mar 2024 | 5.30m | 5.93% |
| Boston Partners Global Investors, Inc.as of 31 Mar 2024 | 3.94m | 4.41% |
| BlackRock Advisors LLCas of 31 Mar 2024 | 3.57m | 3.99% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.14m | 3.51% |
| AllianceBernstein LPas of 31 Mar 2024 | 3.08m | 3.45% |
| Gates Capital Management, Inc.as of 31 Mar 2024 | 2.37m | 2.65% |
| Beck, Mack & Oliver LLCas of 31 Mar 2024 | 2.37m | 2.65% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
